

# Drivers of Glucose and Glutamine Metabolism Reprogramming in Tumor Cells and Their Potential as a Target for Cancer Therapy

Abraham Nigussie Mekuria\*

School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Ethiopia

\*Corresponding author: Abraham Nigussie Mekuria, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Ethiopia, Tel: 251911194519; E-mail: [abrishn@yahoo.com](mailto:abrishn@yahoo.com)

Received: 01 Dec, 2018 | Accepted: 28 Dec, 2018 | Published: 31 Dec, 2018

**Citation:** Mekuria AN (2018) Driver of Glucose and Glutamine Metabolism Reprogramming in Tumor Cells and Their Potential as a Target for Cancer Therapy. *Int J Cancer Res Mol Mech* 4(1): [dx.doi.org/10.16966/2381-3318.141](http://dx.doi.org/10.16966/2381-3318.141)

**Copyright:** © 2018 Mekuria AN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Transformed cells undergo a metabolic transformation to satisfy the demands of growth and proliferation. In this regard, cancer cells prefer to perform glycolysis in the cytosol even in the presence of oxygen, a phenomenon first observed by Otto Warburg and now famously known as “Warburg effect” or “aerobic glycolysis”. Such reprogramming of glucose metabolism has been validated within many tumors, and increased glycolysis facilitates biosynthesis of biomass (e.g., nucleotides, amino acids and lipids) by providing glycolytic intermediates as raw material. Besides the dysregulation of glucose metabolism, metabolic reprogramming in cancer cells has been characterized by aberrant lipid metabolism, amino acids metabolism, mitochondrial biogenesis, and other bioenergetics metabolic pathways. However, the two noticeable characteristics of tumor cell metabolism are the Warburg effect and glutaminolysis, which, respectively, demonstrate the dependence of tumor cells on glucose and glutamine. This review aimed at appraising recent findings related to the drivers of glucose and glutamine metabolism reprogramming, their crosstalk in cancer cells, and their potential in cancer therapy.

**Keywords:** Metabolic reprogramming; Novel targets; Cancer; Glycolysis; Glutaminolysis

## Background

Compared to normal cells, tumor cells show an essentially contrarily accustomed metabolism so as to find ways to proliferate, even though both types of cells use the same nutrients [1,2]. Otto Warburg showed that cancer cells are addicted to glycolysis; they ferment glucose into lactate rather than committing into mitochondrial oxidative phosphorylation (OXPHO), regardless of oxygen tension [3]. He postulated that defect in tumor cells mitochondria resulted in reduced OXPHO [4]. But, this is not the case, according to current understanding. They do, however, adapt their function to the needs of cell proliferation. Mitochondria, in addition to acting as a hub for ATP production, it serves a significant role by synthesizing precursors required for proteins, lipids, and nucleic acids synthesis *via* Krebs's cycle [5-7]. To this end, in the following sections recent findings related to the drivers of glucose and glutamine metabolism reprogramming, their crosstalk in cancer cells, and their potential as cancer therapeutic strategy will be reviewed.

## Underlining Mechanisms

According to, existing literatures pointed out that alterations in numerous signaling pathways and altered expression and mutation of metabolic enzymes are central in mediating the unusual metabolic behavior of cancer cells [8-10].

## Aberrant signaling Pathways

Proliferating cells, i.e. both cancer cells and normal cells exhibit metabolic reprogramming, but, in normal cells, growth factor (GF) signaling-induced alterations to metabolism are responsive to environmental signals and rapidly down-regulated if circumstances are unfavorable for growth [8]. In contrast, in tumor cells, internal and external cues turn out to be decoupled, owing to up-regulation of oncogenic signaling pathways and/or down regulation of tumor suppressor signaling pathways [9] (Figure 1).

It shows various aspects of energy metabolism regulation, including glycolysis, TCA cycle, pentose phosphate, glutaminolysis, fatty acid biosynthesis pathway, PI3K and RAS-MAPK signaling cascade. Three transcription factors, HIF-1, c-Myc and p53, are key regulators and coordinate regulation of cancer metabolism in different ways. 2HG, 2-hydroxyglutarate; 3PG, 3-phospho-glycerate; 6P gluconate, 6-phospho-gluconate; a-KG, a-ketoglutarate; ACLY, acetyl-CoA by ATP-citrate lyase; AKT, v-akt murine thymoma viral oncogene homologue; AMPK, AMP-activated protein kinase; CD44, is a glycoprotein; EGFR, epidermal growth factor receptor; F1,6P, fructose-1,6-bisphosphate; F6P, fructose-6-phosphate; G6P, glucose-6-phosphate; G6PD, glucose-6-phosphate dehydrogenase; Gln, glutamine; GLS, glutaminase; Glu, glutamic acid; GLUT,

glucose transporter; HER2, human epidermal growth factor receptor type 2; HIF, hypoxia-inducible factor; HK, hexokinase; IDH, isocitrate dehydrogenase; IKK, nuclear factor- $\kappa$ B light-chain-enhancer of activated B cells kinase; LDH, lactate dehydrogenase; LKB1, liver kinase B1; MET, hepatocyte growth factor receptor; mTOR, mammalian target of rapamycin; NF- $\kappa$ B, nuclear factor- $\kappa$ B light-chain-enhancer of activated B cells kinase; OH, hydroxy; P, phosphate; PDH, pyruvate dehydrogenase; PEP, phosphoenolpyruvate; PFK, phosphofructokinase; PHD2, prolyl hydroxylase 2; PI3K, phosphatidylinositol 3-kinase; PKM2, pyruvate kinase isozyme type 2; PTEN, phosphate and tensin homolog deleted on chromosome 10; RAF, regulation of alpha-fetoprotein; RAS, rat sarcoma virus peptide; ROS, reactive oxygen species; RTK, receptor tyrosine kinases; Ru5P, ribulose-5-phosphate; sCO<sub>2</sub>, synthesis of cytochrome c oxidase 2; TCA, tricarboxylic acid; TIGAR, Tp53-induced glycolysis and apoptosis regulator; VHL, von Hippel-Lindau tumor suppressor, adapted from Song [9].

**The Phosphoinositide-3-Kinase (PI3K):** Pathway: PI3K is one of the most commonly rearranged signaling pathways in human cancer cells [11]. It could be because of mutation in phosphate and tensin homolog (PTEN), a tumor suppressor gene that inhibits the PI3K pathway [12]. Besides, mutations in the components of the pathway itself have also been associated with PI3K activation [13]. Abnormal signaling through receptor tyrosine kinases (RTK) upstream to the PI3K pathway have been also associated with aberrant activation of the PI3K pathway [12]. In this regards, activation of the pathway directly affects cellular metabolism like stimulation of glycolysis possibly *via* up regulating glucose transporters proteins expression and membrane translocation, as well as by activating crucial glycolytic enzymes *via* phosphorylation as shown in figure 1 [9,14]. Besides, indirectly through activation of mammalian target of rapamycin (mTOR) [15], that is known to regulate transcription factors such as hypoxia-inducible factor-1 (HIF1) leads to HIF1-dependent metabolic changes as shown in figure 1 and table 1 [9,16,17].

**Liver Kinase B1 (LKB1)/Adenosine Monophosphate-Activated Protein Kinase (AMPK) Pathways:** Activation of the pathway known to regulate energy metabolism and growth, stimulating gene expression for extensive changes in metabolic programming, suppressing protein synthesis, and stimulating fatty acid oxidation to replenish ATP [18,19]. For instance, AMPK directly phosphorylates peroxisome proliferator activated receptor gamma (PPAR- $\gamma$ ) coactivator-1- $\alpha$  (PGC-1 $\alpha$ ), a transcriptional coactivator that controls several metabolic genes and mitochondria formation (Figure 1) [20]. However, loss of activity of AMPK has been associated with promotion of carcinogenesis *via* increasing the glycolytic pathway in tumor cells. This promotes a metabolic shift toward the Warburg effect [21]. Moreover, loss of LKB1 expression in tumor cells reduces the AMPK signaling, making cells more sensitive to low nutrient level, and leading to unregulated metabolism and cell growth in energetically stressful conditions [22-25]. This might promote tumorigenesis, as it leads to elevated glucose and glutamine flow, rising ATP levels, and a metabolic switch to aerobic glycolysis.

**Hypoxia-Inducible Factor-1:** HIF1 has been recognized as a key mediator of metabolic response to hypoxia [9]. It is a heterodimer composed of constitutive, stable  $\beta$  subunits and unstable  $\alpha$  subunits, which are synthesized yet, degraded under presence of adequate oxygen due to the sequential action of oxygen-dependent prolyl hydroxylases (PHDs) and the VHL ubiquitin ligase (Figure 1). It functions as a transcriptional activator and enhances expression many

oncogenes, including vascular endothelial growth factor (VEGF), which promotes angiogenesis; epidermal growth factor (EGF); insulin like growth factor-2 (IGF-2); transforming growth factor beta (TGF- $\beta$ ) [26], which stimulates growth and cell survival, and most importantly reprogram energy metabolism as shown in table 1 [9].

**Myc:** There is difference between normal cells and cancer cells in the level of expression of Myc [10]. According to studies, expression of Myc is induced by GF stimulation in normal cells, whereas in cancer cells there is over expression of Myc without regarding to GF signaling and this over expression is estimated to occur in 70% of human tumors [27,28]. Subsequently, over activity of Myc stimulates energy generation and precursor synthesis required for fast proliferation tumor cells [10]. Similar to HIF, Myc reprogram energy metabolism by altering target gene expression (Table 1).

**p53:** It plays an essential part in regulating the activities of glycolysis and OXPHOS (Table 1), in addition to its role in DNA damage response and apoptosis [29]. In general, p53 decreases the glycolytic rate, however, mutation or suppression of p53 frequently occurs in cancer, which results in losing control of its functions, thus promoting glycolysis. Surprisingly, mutant p53 inhibit mitochondrial respiration by down-regulating expression of cytochrome c oxidase 2 (sCO<sub>2</sub>) and Glutaminase 2 (GLS2) [30]. Moreover, it activates AKT and HIF, which are effectors downstream of PI3K [31].

**Table 1:** Target genes of HIF, c-Myc and p53 associated with energy metabolism [9].

Pathways	Target genes	Transcription factors
Transporter	Glucose transporter 1	HIF, c-Myc & p53
	Glucose transporter 2	c-Myc
	Glucose transporter 3	HIF & p53
	Glucose transporter 4	c-Myc & p53
Glycolysis	Hexokinase 2	HIF, c-Myc & p53
	Phosphofructokinase 1	HIF & c-Myc
	Aldolase A	HIF & c-Myc
	GAPDH	HIF & c-Myc
	Phosphoglycerate kinase 1	HIF & c-Myc
	Phosphoglycerate mutase	p53
	Enolase 1	HIF & c-Myc
	Pyruvate kinase M2	HIF & Myc
Pentose phosphate	Lactate dehydrogenase A	HIF & c-Myc
	Transketolase	HIF
TCA cycle	Transketolase-like protein 2	HIF
	Pyruvate dehydrogenase kinase 1	HIF & c-Myc
Others	Glutaminase 2	p53
	Carbomyl phosphate synthetase aspartate transcarbomylase & dihydroorotase	c-Myc
	Serine hydroxymethyl transferase	c-Myc
	Fatty acid synthase	c-Myc
	Ornithine decarboxylase	c-Myc

**Bcl-2 Proteins:** Accumulated body of evidence has shown the involvement of the apoptotic mediator, B cell lymphoma/leukemia-2 (Bcl-2) proteins in reprogramming cancer cells metabolism [32-34]. A study done by Danial et al. [32] reported integration between glycolysis and apoptosis pathway due observation of mitochondria associated glucokinase (in the liver) with the pro-apoptotic protein Bcl-2/Bcl-xL-associated agonist of cell death (BAD). The study revealed that, glucokinase activation *via* direct interaction with BAD especially in response to phosphorylation of BAD by Akt, downstream of PI3K pathway. However, glucokinase inhibits BAD's pro-apoptotic activity when it bounds with BAD in its phosphorylated form. But, dephosphorylated BAD will dissociate from it, and able to interact with the anti-apoptotic protein Bcl-2/Bcl2-like 1, L isoform (Bcl-xL) and stimulate programmed cell death. In this regard, binding of BAD to mitochondria associated glucokinase stimulate glucokinase and glycolysis activity that could be considered as one driver of metabolic reprogramming in cancer cells, in addition to preventing its pro-apoptotic functions [33-35].

Furthermore, a pro-apoptotic BH3-containing protein known as damage protein (NOXA) also play a part in metabolic control. According to a study done by Lowman et al. [36], when there is elevation in of glucose level, NOXA will be phosphorylated by cyclin dependent kinase 5 (CDK5) that leads to localization of this pro-apoptotic protein within the cytoplasm and making it unable to accomplishing its pro-apoptotic functions. As the study found out the protein rather form complex with the anti-apoptotic Bcl-2 protein myeloid cell leukemia-1 (Mcl-1) and stimulates improved glucose metabolism and enhances metabolism *via* the PPP, favoring synthesis ribose sugar and NADPH. Furthermore, subsequent studies showed that over expression of NOXA in tumor cells, and over activity of CDK5 to promote tumor growth and survival, specifically in thyroid and neuroendocrine tumors [37,38].

### Metabolic Enzymes

In addition to activation of oncogenes and loss of tumor suppressor pathways, mutations in key metabolic enzymes as well as preferential expression of specific isoforms of metabolic enzymes can provide cancer cells a mechanism to select for metabolic alterations during tumorigenesis [1,2,39].

**Pyruvate Kinase M2:** Recent studies reported that, PK plays a crucial role in reprogramming of glycolytic metabolism. Four mammalian PK isoenzymes (M1, M2, liver isoform (L) and RBC isoform (R)) have been identified and distributed in diverse cell types [40]. The muscle isoform (PKM1) is a constitutively active tetrameric form that is found in normal adult cells, whereas PKM2 forms less active dimers as well as tetramers and found in differentiated tissues and normal proliferating cells [10].

To form the active tetramer, PKM2 requires fructose-1, 6-bisphosphate (F-1, 6 BP). Its tetramer form has high affinity to PEP and leads to improved production of pyruvate [41]. Meanwhile, studies done using cancer cells pointed out that, PKM2 conversion from the tetramer to less active dimer by phosphorylation mediated tyrosine kinases by at tyrosine 105 sites in the enzyme that leads to a conformational change and dissociation of F-1, 6 BP. The PKM2 conformational change caused by phosphorylation leads to FBP release and conversion of the enzyme from the tetramer to the less active dimer form [42,43]. Hence, in tumor cells, PKM2 is predominantly available in its less active dimeric form, this leads to accumulation of glycolytic intermediates upstream to PK. Subsequently, it causes

diversion of these intermediates into anabolic pathways which hasten active proliferation of cancer cells as shown in figure 1 [9,41]. In contrast, replacement of embryonic and tumor isoform (PKM2) by PKM1 in tumor cell lines renders them less glycolytically active and diminishes tumor xenograft growth, suggesting that PKM2 might be responsible for the Warburg effect [43,44].

On the other hand, PKM2 has been shown to support tumor growth *via* "non-metabolic" attributes [45-47]. For instance, in a study done by Luo et al. [45], PKM2 shown to interact with HIF1 $\alpha$  within the nucleus and as reported by the study this interaction enhances transcriptional activity of HIF1 $\alpha$ . This in turn leads to enhanced expression of target genes, including, GLUT1, PKM2, and LDHA. It is therefore, the study revealed a "positive feedback loop" mechanism that reprograms the glucose metabolism. Similarly, Yang et al. [46] showed that, activation of EGFR resulted in translocation of PKM2 into nucleus where it is associated with phosphorylated  $\beta$ -catenin to form a complex, which enhanced cyclin D1 and c-Myc expression. These findings underscore the importance of the integrated metabolic and non-metabolic functions of PKM2 in tumorigenesis.

**Isocitrate Dehydrogenase (IDH):** IDH mutations can be seen as a case where a single point mutation (R132) affecting cellular metabolism is selected in cancer cells. In fact, IDH1 mutations were recognized in gliomas and acute myeloid leukemias (AML) [47,48]. It has been known that oxidative decarboxylation of isocitrate by non-mutant IDH1 generates  $\alpha$ -ketoglutarate ( $\alpha$ -KG) and NADPH, but not the case concerning the mutant IDH1 [49]. In this regard, Dang et al. [50] using in human malignant gliomas revealed that, the mutant IDH1 reduces  $\alpha$ -KG to 2-hydroxyglutarate (2-HG) by consuming NADPH rather than generation. In AML, both the cytosolic IDH1 and the mitochondrial analogue IDH2 are commonly mutated [51]. One of the consequences of this change regarding tumorigenesis is that, stabilization of the oncogene HIF-1 $\alpha$ , since for its degradation  $\alpha$ -KG is required by PDH2 [26]. Moreover, 2-HG was shown to act as a competitive inhibitor of  $\alpha$ -KG-dependent demethylases, including histone demethylases and the TET family of 5-methylcytosine hydroxylases, affecting CpG island hypermethylation. This links the oncogenic effect of IDH1 mutations to epigenetic regulation [52,53].

**Succinate Dehydrogenase and Fumarate Hydratase:** It has been known that, Krebs's cycle enzymes SDH and FH catalyze the conversion of succinate to fumarate and fumarate to malate, respectively. But, mutant form of these enzymes has been associated with carcinogenesis [54]. In this regard, Pollard et al. [55] reported frequent germline mutation in FH regarding familial cancer syndromes, renal, skin, and uterine cancers. In the same study, mutations in these enzymes caused accumulation of their substrate and these substrates i.e. fumarate and succinate ones accumulated can act as oncogenes when the traverse the inner mitochondrial membrane and enter the cytosol by dioxygenases and prolyl hydroxylases, which are known to be involved in the degradation of the oncogene HIF-1 $\alpha$  under normoxic environment [2].

### Metabolic Targeting for Cancer Therapy

During the past decade, the metabolic rewiring of cancer cells has been viewed as a promising source of novel drug targets (Table 2).

**Targeting Glucose Metabolism:** As shown in table 2, targeting GLUTs, HK-II, PFK-1, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), PKM2, and Krebs's cycle mutant enzymes has been tried as part of development of anticancer drugs to modulate glucose metabolism in tumors [56-79]. For instance, several compounds,

**Table 2:** Altered enzymes and transporter proteins in glucose and glutamine metabolism and possible drivers in various types of cancers.

Metabolic enzyme or transporter protein	Alteration in cancer cells	Consequence of alteration	Possible drivers	Example cancer types	Compounds under investigation	References
Glucose transporters	Overexpression of GLUT-1, -3, -4 & -12	Facilitate glucose uptake by cancer cells	Over activity of MYC, AKT, HIF-1 $\alpha$ , & LOF mutation of p53	Brain, breast, head, neck, bladder, renal, colorectal, lung, gastric, ovarian, OED, OSCC, & laryngeal	Phloretin, WZB117, Fasentin	[56-60]
Hexokinase	Over expression of HK II	Facilitate glucose metabolism & also functions as a protective signaling molecule	Over activity of MYC, & AKT	Breast, colon, lung, liver, ovarian, cervical, pancreatic, glioblastoma, & thyroid	2-DG	[61-64]
	Under expression of HK I	Accelerate tumor growth & metastasis	Over activity of MYC, & AKT	Cervical		[61]
Phosphofruktokinase 1	Over expression of pfkfb-3	Increased production of F2, 6BP, a potent allosteric activator of PFK-1	Over activity of MYC, & AKT	Breast, colon, ovarian, thyroid, head, neck & squamous cell	PFK158	[67,68]
Pyruvate kinase	Over expression of PKM2	Causes accumulation & diversion of glycolytic intermediates upstream to PK into anabolic pathways; enhances transcriptional activity of HIF1 $\alpha$	Over activity of HIF, EGFR & LOF mutation of p53	Lung, liver, colon, thyroid, kidney & bladder	TLN-232/CAP-232, Lapachol	[41-46,69]
Pyruvate dehydrogenase kinase	Over expression of PDK1-3	Reduce flux of pyruvate into mitochondria	Over activity of MYC, HIF-1 $\alpha$ , & LOF mutation of p53	glioblastoma, breast, melanoma, cervical, colon, & ovarian,	DCA	[73-77]
Lactate dehydrogenase	Over expression of LDH-A	Prevent buildup of lactate inside cancer cell	Over activity of MYC, HIF-1 $\alpha$ , & LOF mutation of p53	Liver, colon, lung, & pancreatic	FX11	[34,70,71]
Monocarboxylate transporters	Over expression of MCT1 & MCT4	Facilitate lactic acid effuse from tumor cells	Over activity of MYC & LOF mutation of p53	Prostate, gastric, lung, breast, colon	$\alpha$ -cyano-4-hydroxy-cinnamic acid	[70-72]
Glutamine transporter proteins	Over expression of SLC1A5 & LAT1	Sustain glutamine need of cancer cells	Over activity of MYC & LOF mutation of p53	Breast, colon, lung, melanoma, neuroblastoma, glioblastoma, & prostate	KM8094, BCH, GPNA	[83-88]
Glutaminase	Over expression of GLS1	Maintain a functioning TCA cycle	Over activity of MYC, KRAS, Rho GTPases & LOF mutation of p53	Colon, breast, lung, cervix, brain; human B lymphoma, prostate, acute myeloid leukemia, myeloma, & gliomas	BPTES, CB-83958, & compound 968	[89-96]
Glutamate dehydrogenase	Over expression of GLUD	Maintain a functioning TCA cycle	Over activity of MYC	Gliomas, leukemias, breast, lung & colon	EGCG, R162	[74,96]
Isocitrate Dehydrogenase	GOF mutation of IDH1, & IDH2	Production of 2HG from $\alpha$ -KG & resulted in stabilization of HIF-1 $\alpha$	-	Gliomas & acute myeloid leukemias	AG-221	[48-51]
Succinate Dehydrogenase & Fumarate Hydratase	LOF mutations FH, SDH B, -C & -D	Increased succinate &/or fumarate causes stabilization of HIF-1 $\alpha$	-	Renal, skin, & uterine	-	[54,55]

Glucose transporter (GLUT); fructose-2, 6-bisphosphate (F2, 6BP); pyruvate kinase (PK); 2-deoxyglucose (2-DG); Dichloroacetate (DCA); Hexokinase (HK); Loss of function (LOF); Gain-of-function (GOF); oral epithelial dysplasia (OED); oral squamous cell carcinoma (OSCC); Pyruvate dehydrogenase kinase (PDK).

2-hydroxyglutarate (2HG);  $\alpha$  ketoglutarate ( $\alpha$ -KG); Succinate Dehydrogenase (SDH); Fumarate Hydratase (FH); Isocitrate Dehydrogenase (IDH); Solute carrier family A1 member 5 (SLC1A5); L-type amino acid transporter 1 (LAT1); Glutaminase 1 (GLS1); Monocarboxylate transporters (MCT); Lactate dehydrogenase (LDH); 2-aminobicyclo-(2, 2,1)-heptane-2-carboxylic acid (BCH); gamma-l-glutamyl-p-nitroanilide (GPNA); bis-2-[5-phenylacetamido-1, 2, 4-thiadiazol-2-yl] ethyl sulfide (BPTES), Epigallocatechin gallate (EGCG); Glutamate dehydrogenase (GLUD); Loss of function (LOF); Gain-of-function (GOF).




Figure 1: Signaling networks and their regulation of metabolism in cancer cells.

including, phloretin, WZB117 and fasentin has been demonstrated antitumor effects in preclinical studies by inhibiting GLUTs. However, selectivity of such drugs against tumors is under question because they are ubiquitously expressed in mammalian cells [56]. Moreover, 2-deoxyglucose (2-DG), a glucose analogue has been identified as a small molecule that inhibits HK and glycolysis according to *in vitro* and *in vivo* studies as reviewed by Xi et al. [65]. Furthermore, in study done by Zhu et al. [66] 2-DG showed in improved inhibition of growth, migration, invasion and cell cycle arrest when combined with metformin against ovarian cancer cell lines *via* p38 MAPK/JNK signaling pathway.

On the other hand, mutation in the Krebs's cycle enzymes IDH, FH, and SDH have been identified in different cancer types [78,74]. Novel compounds like that target the gain-of-function activity of mutant IDH have recently been shown to have success in preclinical and clinical settings [78], however, inhibiting mutant FH and SDH with small molecules has been unrealistic because these are loss of function mutations [74]. Accordingly, AG-221, inhibitor of mutant IDH2 has been shown to decrease the production of 2HG and cause tumor cells to differentiate towards a more normal phenotype and it is early phase clinical trials [79].

**Targeting Glutamine Metabolism:** The idea of interrupting the supply or utilization of the conditionally-essential amino acid glutamine in order to fight cancer dates back several decades and is based on its high concentration in plasma as well as the selective vulnerability of a variety of malignant cells to glutamine depletion [80,81]. In this regard, studies has been investigating several small

molecules which inhibits glutamine transporter proteins and glutaminase enzyme that play a great role in cancer cell glutamine metabolism as shown in table 2 [82-94].

For instance, it has been recognized that, solute carrier family A1 member 5 (SLC1A5) and L-type amino acid transporter 1 (LAT1) which are involved glutamine transport in the cell shown to be up-regulated in malignancies [82,83]. To inhibit glutamine uptake by tumor cells different compounds have been tested *in vitro* and *in vivo* [84]. In a study done by Hassanein et al. [85] aimed at evaluating SLC1A5 as a potential target and candidate biomarker predictive of survival and response to therapy, targeting was examined in a panel of NSCLC and human bronchial cell lines by RNA interference and by a small molecular inhibitor, gamma-l-glutamyl-p-nitroanilide (GPNA). In the study, inactivation of SLC1A5 genetically or pharmacologically has been shown to decrease glutamine consumption, inhibit cell growth, and also induce autophagy and apoptosis in a subgroup of NSCLC cell lines that over express SLC1A5. Moreover in the same study targeting SLC1A5 has been shown to decrease tumor growth in NSCLC xenografts. Similarly, in a recent study reported by Kasai et al. [86] has been the anti-tumor efficacy of a novel anti-SLC1A5 humanized monoclonal antibody, KM8094 against gastric cancer by inhibiting glutamine uptake. On the other hand, a study done by Imai et al. [87] using inhibitor of LAT1, 2-aminobicyclo-(2, 2,1)-heptane-2-carboxylic acid (BCH), demonstrated reduction in viability of on-small cell lung cancer cell lines as well as, co-administration of gefitinib with BCH reduced the viability of the cells more than either agent alone. The authors reported that inhibition of LAT1 reduced the level of phosphorylation of mTOR, p70S6K and 4EBP1.

Moreover, it is known that GLS is required to generate glutamate from glutamine during glutamine metabolism is GLS [1]. GLS has been inhibited using small molecule inhibitors such as bis-2-[5-phenylacetamido-1, 2, 4-thiadiazol-2-yl] ethyl sulfide (BPTES), CB-83958 and compound 968 [88-90]. In these studies inhibition has been shown to significantly suppress tumor growth in several experimental models including breast cancer and lymphoma. Moreover, a recent study done by Song et al. [91] demonstrated that, loss of GLS1 expression by RNAi shown to decrease proliferation and survival of colorectal cancer (CRC) cells due to decrease in ATP levels and increases ROS level.

However, in a study done by Cheng et al. [89] silencing of GLS inhibits cell proliferation but fails to eliminate glioblastoma cells in both *in vitro* and *in vivo* models. The same study found out that induction of a compensatory anaplerotic mechanism mediated by pyruvate carboxylase (PC), allows the tumors to use glucose-derived pyruvate instead of glutamine for anaplerosis. Furthermore, Phannasil et al. [92] reported that expression of PC in cancerous areas of breast tissue at higher levels than in the non-cancerous areas by examining the expression of PC using Immunohistochemistry of paraffin-embedded breast tissue sections of fifty seven breast cancer patients with different stages of cancer progression. In this regard, dual targeting of both GLS and PC could produce synergistic activity in arresting growth of tumors having glutamine addiction.

### Current Challenges and Future Perspectives

Realizing the intricate nature of metabolic links and how different tumors adjust these processes to satisfy their metabolic demands will be one of the most important challenges in exploiting cancer metabolism target for cancer therapy. In this regard, explicit knowledge regarding most feasible targets and their control and cross-talk at different levels of regulation will transform the efforts of current studies in to fruit i.e. producing a successful anticancer agent targeting cancer metabolism. The other issue that could be a challenge and should be addressed in the future is selectivity, because highly proliferating cells like T lymphocyte cells have similarity in metabolic profiles like cancer cells, it is therefore, understanding the critical difference between cancer and highly proliferating normal cells will have paramount importance in avoiding toxicity. On the other hand, combining metabolic inhibitors with the currently available drugs which have been associated with cell death *via* oxidative stress, might leads to synergistic effect by arresting pro-survival mechanisms *via* generation of ATP as well as reducing powers like NADPH *via* PPP.

### Conflict of Interests

The author declares that there is no conflict of interests regarding the publication of this paper.

### Acknowledgments

The author would like to thank Professor Ephrem Engidawork for his help and making this review possible.

### References

- Vazquez A, Kamphorst JJ, Markert EK, Schug ZT, Tardito S, et al. (2016) Cancer metabolism at a glance. *J Cell Sci* 129: 3367-3373.
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144: 646-674.
- Warburg O (1956) On the origin of cancer cells. *Science* 123: 309-314.
- Weinhouse S (1956) On respiratory impairment in cancer cells. *Science* 124: 267-269.
- Vazquez A, Liu J, Zhou Y, Oltvai ZN (2010) Catabolic efficiency of aerobic glycolysis: The Warburg effect revisited. *BMC Syst Biol* 4: 58.
- Locasale JW, Cantley LC (2011) Metabolic flux and the regulation of mammalian cell growth. *Cell Metab* 14: 443-451.
- Ahn CS, Metallo CM (2015) Mitochondria as biosynthetic factories for cancer Proliferation. *Cancer Metab* 3: 1.
- Azharuddin M, Sharon D (2016) Role of oncogenes and tumor suppressors in metabolic reprogramming and cancer therapeutics: A review. *JCTI* 4: 1-27.
- Soga T (2013) Cancer metabolism: Key players in metabolic reprogramming. *Cancer Sci* 104: 275-281.
- Cantor JR, Sabatini DM (2012) Cancer cell metabolism: One hallmark, many faces. *Cancer Discov* 2: 881-898.
- Goncalves E, Bucher J, Ryll A, Niklas J, Mauch K, et al. (2013) Bridging the layers: Towards integration of signal transduction, regulation and metabolism into mathematical models. *Mol Biosyst* 9: 1576-1583.
- Wong KK, Engelman JA, Cantley LC (2010) Targeting the PI3K signaling pathway in cancer. *Curr Opin Genet Dev* 20: 87-90.
- Plas DR, Thompson CB (2005) Akt-dependent transformation: there is more to growth than just surviving. *Oncogene* 24: 7435-7442.
- Robey RB, Hay N (2009) Is Akt the "Warburg kinase"? Akt-energy metabolism interactions and oncogenesis. *Semin Cancer Biol* 19: 25-31.
- Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. *Cancer Cell* 12: 9-22.
- Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. *Cancer Res* 64: 3892-3899.
- Fan Y, Dickman KG, Zong WX (2010) Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. *J Biol Chem* 285: 7324-7333.
- Faubert B, Vincent EE, Poffenberger MC, Jones RG (2015) The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. *Cancer Lett* 356: 165-170.
- Faubert B, Vincent E, Griss T, Samborska B, Izreig S, et al. (2014) Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells *via* HIF-1 $\alpha$ . *Proc Natl Acad Sci USA* 111: 2554-2559.
- Sanli T, Steinberg GR, Singh G, Tsakiridis T (2014) AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. *Cancer Biol Ther* 15: 156-169.
- Grahame DH (2014) AMP-activated protein kinase: A key regulator of energy balance with many roles in human disease. *J Intern Med* 276: 543-559.
- Faubert B, Boily G, Izreig S, Griss T, Samborska B, et al. (2013) AMPK is a negative regulator of the Warburg effect and suppresses tumor growth *in vivo*. *Cell Metab* 17: 113-124.
- Zhao R, Xu Z (2014) Targeting the LKB1 tumor suppressor. *Curr Drug Targets* 15: 32-52.
- Whang YM, Park SI, Trenary IA, Egnatchik RA, Fessel JP, et al. (2016) LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. *Oncogene* 35: 856-866.

25. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, et al. (2013) LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. *Cancer Cell* 23: 143-158.
26. Brahimi-Horn MC, Bellot G, Pouyssegur J (2011) Hypoxia and energetic tumor metabolism. *Curr Opin Genet Dev* 21: 67-72.
27. Wahlstrom T, Henriksson MA (2015) Impact of MYC in regulation of tumor cell metabolism. *Biochim Biophys Acta* 1849: 563-569.
28. Li B, Simon MC (2013) Molecular pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. *Clin Cancer Res* 19: 5835-5841.
29. Kruiswijk F, Labuschagne CF, Vousden KH (2015) p53 in survival, death and metabolic health: a lifeguard with a licence to kill. *Nat Rev Mol Cell Biol* 16: 393-405.
30. Guo XE, Ngo B, Modrek AS, Lee WH (2014) Targeting tumor suppressor networks for cancer therapeutics. *Curr Drug Targets* 15: 2-16.
31. Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS (2014) Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. *Curr Drug Targets* 15: 80-89.
32. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, et al. (2003) BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. *Nature* 424: 952-956.
33. Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, et al. (2014) RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. *Sci Signal* 7: ra122.
34. Sastry KS, Al-Muftah MA, Li P, Al-Kowari MK, Wang E, et al. (2014) Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. *Cell Death Differ* 21: 1936-1949.
35. Chang CY, Shen CC, Su HL, Chen CJ (2011) Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. *J Neurooncol* 105: 507-522.
36. Lowman XH, McDonnell MA, Kosloske A, Odumade OA, Jenness C, et al. (2010) The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. *Mol Cell* 40: 823-833.
37. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, et al. (2013) The role of Cdk5 in neuroendocrine thyroid cancer. *Cancer Cell* 24: 499-511.
38. Lin H, Chen MC, Chiu CY, Song YM, Lin SY (2007) Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. *J Biol Chem* 282: 2776-2784.
39. Tran Q, Lee H, Park J, Kim SH, Park J (2016) Targeting Cancer Metabolism - Revisiting the Warburg Effects. *Toxicol Res* 32: 177-193.
40. Rahman M, Hasan MR (2015) Cancer Metabolism and Drug Resistance. *Metabolites* 5: 571-600.
41. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E (2005) Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin Cancer Biol* 15: 300-308.
42. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature* 452: 230-233.
43. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, et al. (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. *Sci Signal* 2: ra73.
44. Yang W, Xia Y, Hawke D, Li X, Liang J, et al. (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. *Cell* 150: 685-696.
45. Luo W, Hu H, Chang R, Zhong J, Knabel M, et al. (2011) Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. *Cell* 145: 732-744.
46. Yang W, Xia Y, Ji H, Zheng Y, Liang J, et al. (2011) Nuclear PKM2 regulates  $\beta$ -catenin transactivation upon EGFR activation. *Nature* 480: 118-122.
47. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. *Nature* 463: 364-368.
48. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 360: 765-773.
49. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. *N Engl J Med* 361: 1058-1066.
50. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 462: 739-744.
51. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, et al. (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. *Proc Natl Acad Sci USA* 108: 3270-3275.
52. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* 17: 225-234.
53. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, et al. (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. *J Neurooncol* 107: 197-205.
54. Griffin JL, Shockcor JP (2004) Metabolic profiles of cancer cells. *Nat Rev Cancer* 4: 551-561.
55. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. *Hum Mol Genet* 14: 2231-2239.
56. Sborov DW, Haverkos BM, Harris PJ (2015) Investigational cancer drugs targeting cell metabolism in clinical development. *Expert Opin Investig Drugs* 24: 79-94.
57. Feng W, Cui G, Tang CW, Zhang XL, Dai C, et al. (2017) Role of glucose metabolism related gene GLUT1 in the occurrence and prognosis of colorectal cancer. *Oncotarget* 8: 56850-56857.
58. Zhang TB, Zhao Y, Tong ZX, Guan YF (2015) Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45. *Int J Clin Exp Med* 8: 2423-2428.
59. Feitosa SG, Viana KF, Luna ECM, Costa FWG, Cavalcante RB, et al. (2018) Immunohistochemical Evaluation of GLUT-3 and GLUT-4 in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. *Asian Pac J Cancer Prev* 19: 1779-1783.
60. Jiang T, Zhou M, Fan J (2018) Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells *in vitro*. *Onco Targets Ther* 11: 7865-7872.
61. Tseng PL, Chen CW, Hu KH, Cheng HC, Lin YH, et al. (2018) The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy *via* deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition. *Oncotarget* 9: 18949-18969.

62. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, et al. (2013) Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. *Cancer Cell* 24: 213-228.
63. Gershon TR, Crowther AJ, Tikunov A, Garcia I, Annis R, et al. (2013) Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. *Cancer Metab* 1: 2.
64. Gu L, Yi Z, Zhang Y, Ma Z, Zhu Y, et al. (2017) Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance *via* N-linked glycosylation inhibition under normoxia. *Oncotarget* 8: 30978-30991.
65. Xi H, Kurtoglu M, Lampidis TJ (2014) The wonders of 2-deoxy-D-glucose. *IUBMB Life* 66: 110-121.
66. Zhu J, Zheng Y, Zhang H, Sun H (2016) Targeting cancer cell metabolism: The combination of metformin and 2-Deoxyglucose regulates apoptosis in ovarian cancer cells *via* p38 MAPK/JNK signaling pathway. *Am J Transl Res* 8: 4812-4821.
67. Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, et al. (2014) 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis *via* Cdk1-mediated phosphorylation of p27. *Cell Death Dis* 5: e1337.
68. Li HM, Yang JG, Liu ZJ, Wang WM, Yu ZL, et al. (2017) Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma. *J Exp Clin Cancer Res* 36: 7.
69. Shankar Babu M, Mahanta S, Lakhter AJ, Hato T, Paul S, et al. (2018) Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2. *PLoS One* 13: e0191419.
70. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, et al. (2010) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proc Natl Acad Sci USA* 107: 2037-2042.
71. Zhai X, Yang Y, Wan J, Zhu R, Wu Y (2013) Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. *Oncology Rep* 30: 2983-2991.
72. Hamdan L, Arrar Z, Al Muataz Y, Suleiman L, Négrier C, et al. (2013) Alpha Cyano-4-Hydroxy-3-Methoxycinnamic acid inhibits proliferation and induces apoptosis in human breast cancer cells. *PLoS ONE* 8: e72953.
73. Duan Y, Zhao X, Ren W, Wang X, Yu KF, et al. (2013) Antitumor activity of dichloroacetate on C6 glioma cell: *in vitro* and *in vivo* evaluation. *Onco Targets Ther* 6: 189-198.
74. Kishton RJ, Rathmell JC (2015) Novel Therapeutic Targets of Tumor Metabolism. *Cancer J* 21: 62-69.
75. Woo SH, Seo S, Park Y, Kim EK, Seong M, et al. (2016) Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells *via* down-regulation of the epidermal growth factor receptor. *Oncotarget* 7: 59809-59819.
76. Saed GM, Fletcher NM, Jiang ZL, Abu-Soud HM, Diamond MP (2011) Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress. *Reprod Sci* 18: 1253-1261.
77. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, et al. (2010) Metabolic modulation of Glioblastoma with Dichloroacetate. *Sci Transl Med* 2: 31ra34.
78. Mondesir J, Willekens C, Touat M, de Botton S (2016) IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. *J Blood Med* 7: 171-180.
79. Yen K, Travins J, Wang F, David MD, Artin E, et al. (2017) AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. *Cancer Discov* 7: 478-493.
80. Choi Y, Park K (2018) Targeting glutamine metabolism for cancer treatment. *Biomol Ther* 26: 19-28.
81. Li C, Zhang G, Zhao L, Ma Z, Chen H (2016) Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer. *World J Surg Oncol* 14: 15.
82. Liu Y, Yang L, An H, Chang Y, Zhang W, et al. (2015) High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. *Sci Rep* 5: 16954.
83. Hayase S, Kumamoto K, Saito K, Kofunato Y, Sato Y, et al. (2017) L-type amino acid transporter 1 expression is upregulated and associated with cellular proliferation in colorectal cancer. *Oncol Lett* 14: 7410-7416.
84. Giuliani N, Chiu M, Bolzoni M, Accardi F, Bianchi MG, et al. (2017) The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma. *Expert Opin Ther Targets* 21: 231-234.
85. Hassanein M, Qian J, Hoeksema MD, Wang J, Jacobovitz M, et al. (2015) Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer. *Int J Cancer* 137: 1587-1597.
86. Kasai N, Sasakawa A, Hosomi K, Poh TW, Chua BL, et al. (2017) Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer. *Am J Transl Res* 9: 3399-3410.
87. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, et al. (2010) Inhibition of L-type Amino Acid Transporter 1 Has Antitumor Activity in Non-small Cell Lung Cancer. *Anticancer Res* 30: 4819-4828.
88. Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsén R, et al. (2015) Targeting glutaminolysis has anti-leukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. *Blood* 126: 1346-1356.
89. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, et al. (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. *Proc Natl Acad Sci U S A* 108: 8674-8679.
90. Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, et al. (2015) Resistance to BRAF inhibitors induces glutamine dependency in melanomacells. *Mol Oncol* 78: 34-37.
91. Song Z, Wei B, Lu C, Li P, Chen L (2017) Glutaminase sustains cell survival *via* the regulation of glycolysis and glutaminolysis in colorectal cancer. *Oncol Lett* 14: 3117-3123.
92. Phannasil P, Thuwajit C, Warnnissorn M, Wallace JC, MacDonald MJ, et al. (2015) Pyruvate carboxylase is up-regulated in breast cancer and essential to support growth and invasion of MDA-MB-231 cells. *PLoS One* 10: e0129848.
93. Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoidi I, et al. (2016) Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. *Blood* 128: 667-679.
94. Márquez J, Alonso FJ, Matés JM, Segura JA, Martín-Rufián M, et al. (2017) Glutamine addiction in Gliomas. *Neurochem Res* 42: 1735-1746.